Search
Showing results for "1"
You may have noticed some changes to the phone triage system for Perth Children’s Hospital’s diabetes clinic recently.
A Clinical Nurse Specialist position within Perth Children’s Hospital’s Diabetes Service has been funded as part of the Federal Government’s new Type 1 Diabetes Management in School program.
We’re super excited to welcome Dr Amelia Harray to our research team. Amelia looks forward to strengthening the focus on food research to help children with type 1 diabetes and their families.
Our researchers have been busy. Here's a look at some of their work to be published recently.
It is unknown whether parental occupational exposure to chemicals before during and after pregnancy increases the risk of acute lymphoblastic...
The social and emotional wellbeing of Aboriginal children and young people
Neonatal retrieval networks have adopted time-centric quality metrics as Key Performance Indicators (KPI) for setting and comparing benchmarking standards. Quicker launch time (departure from base), an essential KPI, enables neonatal retrieval teams to rapidly provide higher-level care to sick infants. The Newborn Emergency Transport Services of Western Australia (NETS WA) facilitates neonatal transfers across largest global retrieval area necessitating quicker team launch times for urgent retrievals. NETS WA conducted a quality improvement (QI) study to quicken team launch times for urgent retrievals.
To evaluate real-world glycaemic outcomes in children with type 1 diabetes commencing advanced hybrid closed loop therapy and to explore these outcomes based on the cohort's clinical and socioeconomic characteristics.
This study aimed to assess whether undertaking retrieval was associated with fatigue independent of sleep and circadian disruption. It also aimed to assess the feasibility of routinely measuring the psychomotor vigilance test on neonatal transport. Fatigue is associated with impaired clinician performance and safety.
The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.